
A comprehensive analysis of 47 randomized clinical trials (7714 participants) investigated the impact of stimulant doses on adults with attention-deficit/hyperactivity disorder (ADHD). For methylphenidate, unlicensed doses showed slightly greater symptom reduction but increased adverse event dropouts. Amphetamines exhibited a plateau in symptom reduction with escalating doses, accompanied by elevated adverse event dropouts. Overall, unlicensed doses may not provide substantial benefits over licensed doses for adults with ADHD, cautioning practitioners to consider dose escalation carefully, acknowledging individual variations.
Like
Save
Share